Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment (clinicaltrials.gov) - Mar 31, 2025 - P1 | N=40 | Recruiting | Sponsor: Plus Therapeutics | Not yet recruiting ➔ Recruiting
Enrollment open • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor
|